Similar Papers

Paper Title
Journal
Date
Author
Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.
Lei Gong ... Haitong Wang
Journal of Clinical Oncology | VOL. 41
Lei Gong, et. al.Lei Gong ... Haitong Wang
01 Jun 2023
Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.
Chengixn Liu ... Baosheng Li
Journal of Clinical Oncology | VOL. 43
Chengixn Liu, et. al.Chengixn Liu ... Baosheng Li
01 Feb 2025
SCALE-1: Safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus.
Ning Jiang ... Cheng Kong
Journal of Clinical Oncology | VOL. 40
Ning Jiang, et. al.Ning Jiang ... Cheng Kong
01 Jun 2022
Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.
Liwei Xu ... Qiang Zhao
Annals of Translational Medicine | VOL. 10
Liwei Xu, et. al.Liwei Xu ... Qiang Zhao
01 Mar 2022
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini ... Biagio Ricciuti
Journal for ImmunoTherapy of Cancer | VOL. 13
Alessio Cortellini, et. al.Alessio Cortellini ... Biagio Ricciuti
04 Feb 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Cameron Wood ... Neal Ready
Journal for ImmunoTherapy of Cancer | VOL. 13
Cameron Wood, et. al.Cameron Wood ... Neal Ready
04 Feb 2025
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping ... Yi Zhang
Journal for ImmunoTherapy of Cancer | VOL. 13
Yu Ping, et. al.Yu Ping ... Yi Zhang
04 Feb 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler ... Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer | VOL. 13
Thomas Eigentler, et. al.Thomas Eigentler ... Ulrike Gnad-Vogt
04 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.